Drug Trial Radar · NCT06682611
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Nov 13, 2024
Primary completion
Nov 13, 2026
Study completion Nov 13, 2027
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort expansion stage. Cohorts 5-8 are SYHA1813 monotherapy and only include the expansion cohorts. The primary objective was to evaluate the safety and efficacy of SYHA1813 single agent or in combination with different regimens in unresectable locally advanced or metastatic solid tumors.
Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
SYHA1813Drug
In accordance with the protocol
SG001Drug
In accordance with the protocol
HB1801Drug
In accordance with the protocol
CarboplatinDrug
In accordance with the protocol
CisplatinDrug
In accordance with the protocol
PaclitaxelDrug
In accordance with the protocol
EtoposideDrug
In accordance with the protocol
EverolimusDrug
In accordance with the protocol
RegorafenibDrug
In accordance with the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Up to approximately 2years
- Frequency and severity of TEAE and SAETime frame: Up to approximately 2years
- ORRTime frame: Up to approximately 2 years
- PFSTime frame: Up to approximately 2years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.